CE mark awarded

Article

Oertli?s new surgical platform Faros, has received its CE mark after meeting EU consumer safety, health or environmental requirements. This important step for the platform keeps it on schedule for an expected March 2010 release.

Oertli’s new surgical platform Faros, has received its CE mark after meeting EU consumer safety, health or environmental requirements. This important step for the platform keeps it on schedule for an expected March 2010 release.

According to the company, the surgical platform has been designed from scratch as a combined platform for work on the anterior and posterior eye segments, as well as functioning as a pure phaco machine with permanent upgrade possibilities to the posterior segment. They claims that it fulfils the requirements of the most modern clinics in addition to meeting the challenges facing developing regions.

For further information, visit the company’s website at www.oertli-faros.com

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.